The proposal on the ban of anticoccidials drugs from poultry feed highlights the importance of broiler breeders resistance to Eimeria as a criteria for animal genetic selection. The aim of this study was to compare the resistance between two commercial broiler breeds to Eimeria acervulina. Eight hundred male chicks from two commercial breeds (400 animals each) were housed from 1-42 days of age and randomly divided into 4 treatments with 8 replicates of 25 birds each. Following a factorial design, the treatments were AU, BU (breed A and B, unchallenged), AC and BC (breed A and B, challenged at 14 days of age by gavage with 1 × 10 oocysts of a field strain of E. acervulina). From 1-42 days, feed intake, body weight gain (BWG), feed conversion ratio (FCR), feed efficiency and mean weight (MW) were weekly measured. For the clinical evaluation, feces were sampled from 18 to 24 days for the counting of excreted oocysts and twenty birds per treatment were euthanized at 20 days of age for the scoring of macroscopic lesions in the gut. The breeds did not show statistical differences in performance after the Eimeria challenge in all phases. Breed A presented a higher increase in FCR from 21 to 45 days in comparison to the breed B, which presented a deeper reduction in FI, BWG and MW at all periods post-infection when compared to the breed A. Despite of the challenge, breed A presented better performance indexes (P < 0.05) up to the 28 days of age in comparison to the breed B, however, no significant difference in performance was detected between the breeds at the final age of 42 days. Regardless of the breed, the challenged birds presented significant worsens in all performance parameters from 14 to 42 days of age. The breed B presented a higher (P < 0.05) fecal count of oocysts from 19 to 21 days and higher (P < 0.05) score of macroscopic lesions in the gut at 21 days in comparison to the breed A. The clinical evaluation pointed out a lower resistance of the breed B to the E. acervulina challenge, which could result in significant impacts on the performance in field production conditions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vetpar.2020.109235 | DOI Listing |
Sleep
January 2025
Sleep Research & Treatment Center, Department of Psychiatry & Behavioral Health, Penn State University, College of Medicine, Hershey PA, USA.
Study Objectives: Although heart rate variability (HRV), a marker of cardiac autonomic modulation (CAM), is known to predict cardiovascular morbidity, the circadian timing of sleep (CTS) is also involved in autonomic modulation. We examined whether circadian misalignment is associated with blunted HRV in adolescents as a function of entrainment to school or on-breaks.
Methods: We evaluated 360 subjects from the Penn State Child Cohort (median 16y) who had at least 3-night at-home actigraphy (ACT), in-lab 9-h polysomnography (PSG) and 24-h Holter-monitoring heart rate variability (HRV) data.
Neurosurg Rev
January 2025
Department of Neurosurgery, King's College Hospital Foundation Trust, London, UK.
Minimally invasive parafascicular surgery (MIPS) with the use of tubular retractors achieve a safe resection in deep seated tumours. Diffusion changes noted on postoperative imaging; the significance and clinical correlation of this remains poorly understood. Single centre retrospective cohort study of neuro-oncology patients undergoing MIPS.
View Article and Find Full Text PDFTissue Eng Regen Med
January 2025
Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital, 172 Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.
Background: Traditionally, dental implants require a healing period of 4 to 9 months for osseointegration, with longer recovery times considered when bone grafting is needed. This retrospective study evaluates the clinical efficacy of demineralized dentin matrix (DDM) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) during dental implant placement to expedite the osseointegration period for early loading.
Methods: Thirty patients (17 male, 13 female; mean age 55.
Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.
View Article and Find Full Text PDFUltrasound Obstet Gynecol
January 2025
Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, SAR, China.
Objectives: To compare the maternal hemodynamic profile at 12 + 0 to 15 + 6 weeks' gestation in women who subsequently developed pre-eclampsia (PE) and those who did not, and to assess the screening performance of maternal hemodynamic parameters for PE in combination with the Fetal Medicine Foundation (FMF) triple test, including maternal factors (MF), mean arterial pressure (MAP), uterine artery pulsatility index and placental growth factor.
Methods: This was a prospective case-control study involving Chinese women with a singleton pregnancy who underwent preterm PE screening at 11 + 0 to 13 + 6 weeks' gestation using the FMF triple test, between February 2020 and February 2023. Women identified as being at high risk (≥ 1:100) for preterm PE by the FMF triple test were matched 1:1 with women identified as low risk (< 1:100) for maternal age ± 3 years, maternal weight ± 5 kg and date of screening ± 14 days.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!